Special Issue "Understanding Immune Responses to Viral Hemorrhagic Fever Infections"

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against (re)emerging and Tropical Infections Diseases".

Deadline for manuscript submissions: 30 September 2022 | Viewed by 1026

Special Issue Editors

Dr. Katerina Tsergouli
E-Mail Website
Guest Editor
School of Medicine, Aristotle University of Thessaloniki, 54641 Thessaloniki, Greece
Interests: virology; bacteriology; antimicrobial resistance; infection control; immunology; cytokines
Prof. Dr. Hinh Ly
E-Mail Website
Guest Editor
Department of Veterinary & Biomedical Sciences University of Minnesota, Twin Cities, MN, USA
Interests: hemorrhagic fever viruses; arenaviruses; Lassa fever; host-virus interactions; innate immunity; viral pathogenesis and host defense
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Viral Hemorrhagic Fever (VHF) is a group of acute zoonotic diseases with high mortality rates caused by seven different families of viruses that infect both humans and animals. These include the arenaviruses, bunyaviruses, filoviruses, and flaviviruses. It causes severe infections characterized by a hyperactive immune response that often leads to multiorgan failure and death. These diseases most commonly occur in tropical areas. Some viral hemorrhagic fevers are spread by mosquito or tick bites. The human immune system plays a crucial role in VHF pathogenesis. Studies have demonstrated that suppression of innate immunity can play a critical role in disease development as activation of the mononuclear phagocytic system can result in secretion of pathologic concentrations of cytokines and chemokines, and adaptive immune responses are potentially impaired by infected dendritic cells failing to undergo maturation. Ultimately, injury of the endothelium and coagulopathy are thought to be caused by inflammatory responses and uncontrolled viral replication. However, the specific molecular mechanisms contributing to disease process of VHF remain poorly understood.

In this special issue, we focus on the the host immune response has the potential to improve the diagnosis of viral hemorrhagic fevers and other diseases. It can also accelerate our efforts to understand the underlying molecular mechanisms that lead to pathogenesis and severe disease.

In this Special Issue, original research articles and reviews are welcome.

I/We look forward to receiving your contributions. 

Dr. Katerina Tsergouli
Prof. Dr. Hinh Ly
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • immune response
  • hemorrhagic fever viruses
  • Ebola
  • yellow fever viruses

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Transcriptomics of Acute DENV-Specific CD8+ T Cells Does Not Support Qualitative Differences as Drivers of Disease Severity
Vaccines 2022, 10(4), 612; https://doi.org/10.3390/vaccines10040612 - 14 Apr 2022
Viewed by 822
While several lines of evidence suggest a protective role of T cells against disease associated with Dengue virus (DENV) infection, their potential contribution to immunopathology in the acute phase of DENV infection remains controversial, and it has been hypothesized that the more severe [...] Read more.
While several lines of evidence suggest a protective role of T cells against disease associated with Dengue virus (DENV) infection, their potential contribution to immunopathology in the acute phase of DENV infection remains controversial, and it has been hypothesized that the more severe form of the disease (dengue hemorrhagic fever, DHF) is associated with altered T cell responses. To address this question, we determined the transcriptomic profiles of DENV-specific CD8+ T cells in a cohort of 40 hospitalized dengue patients with either a milder form of the disease (dengue fever, DF) or a more severe disease form (dengue hemorrhagic fever, DHF). We found multiple transcriptomic signatures, one associated with DENV-specific interferon-gamma responding cells and two other gene signatures, one specifically associated with the acute phase and the other with the early convalescent phase. Additionally, we found no differences in quantity and quality of DENV-specific CD8+ T cells based on disease severity. Taken together with previous findings that did not detect altered DENV-specific CD4 T cell responses, the current analysis argues against alteration in DENV-specific T cell responses as being a correlate of immunopathology. Full article
(This article belongs to the Special Issue Understanding Immune Responses to Viral Hemorrhagic Fever Infections)
Show Figures

Figure 1

Back to TopTop